)
Visual
test
ArriVent BioPharma
ArriVent BioPharma (AVBP) investor relations material
ArriVent BioPharma Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary5 Mar, 2026
Executive summary
Advanced firmonertinib with two pivotal Phase 3 programs targeting uncommon EGFR mutations in NSCLC, addressing high unmet need.
ADC pipeline progressed, with ARR-217 in Phase 1 for gastrointestinal cancers and additional ADC candidates moving toward clinical development.
Cash and investments of $312.8 million as of December 31, 2025, expected to fund operations into 3Q 2027.
Financial highlights
Cash and investments totaled $312.8 million at year-end 2025.
Net cash used in operations was $160.6 million in 2025, up from $70.2 million in 2024.
Research and development expenses rose to $153.4 million in 2025, including a one-time upfront payment to Lepu Biopharma.
General and administrative expenses increased to $24.2 million in 2025.
Net loss widened to $166.3 million in 2025 from $80.5 million in 2024.
Outlook and guidance
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026.
Enrollment underway for global pivotal Phase 3 PACC mutant NSCLC study for firmonertinib.
IND filing for first-in-class ADC program ARR-002 planned for first half 2026.
Phase 1 dose escalation for ARR-217 expected to complete and move to dose optimization in second half of 2026.
What factors sharpen FURVENT data timeline?
How will ARR-217 achieve best-in-class potential?
How will cash burn evolve beyond 2025 R&D spike?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ArriVent BioPharma
- Virtual annual meeting to elect directors and ratify auditor, with updated governance and compensation.AVBP
Proxy Filing2 Dec 2025 - Virtual meeting to elect two directors and ratify auditor, with board support for all proposals.AVBPProxy Filing2 Dec 2025
- Net loss increased on higher R&D spend; cash runway extends into mid-2027.AVBPQ3 202510 Nov 2025
- Net loss rose on R&D growth, but strong cash reserves support ongoing clinical progress.AVBPQ2 202511 Aug 2025
- Firmonertinib delivered high response rates and durable CNS benefit in EGFR PACC mutant NSCLC.AVBPStudy Update23 Jun 2025
- Strong clinical progress and $282.9M cash runway support operations into 2026.AVBPQ3 202413 Jun 2025
- Net loss reached $39.3M as cash rose to $298.7M, funding pipeline progress into 2026.AVBPQ2 202413 Jun 2025
- Q1 2025 saw a $64.4M net loss, strong liquidity, and major pipeline and trial progress.AVBPQ1 20256 Jun 2025
- Strong clinical progress and pipeline expansion position ArriVent for pivotal 2025 milestones.AVBPQ4 20245 Jun 2025
Next ArriVent BioPharma earnings date
Q1 202611 May, 2026
ArriVent BioPharma
Next ArriVent BioPharma earnings date
Q1 202611 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage